[ad_1]
TORONTO, ON and CHICAGO, IL–(Newsfile Corp. – April 2, 2024) – Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will participate in the 2024 Bloom Burton & Co. . General Assembly. The Healthcare Investor Conference will be held on April 16-17, 2024.
event: 2024 Bloom Burton & Co. Healthcare Investor Conference
date: April 16-17, 2024
Place: Toronto, Ontario
Introduction to Medexus: Wednesday, April 17, 1:30 pm ET
Medexus CEO Ken d’Entremont and Medexus Chief Financial Officer Marcel Konrad will speak on April 17, 2024 at 1:30 pm ET and will participate in in-person one-on-one meetings throughout the conference.
Live and recorded webcasts of the Medexus presentation will be available in the Investor News and Events section of the Medexus website or through the following link:
https://wsw.com/webcast/bloomburton9/mdp.to/3096792
About Madex
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease therapeutic solutions. Medexus is currently focused on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy and dermatology. For more information about Medexus and its product portfolio, please see the company’s corporate website at www.medexus.com and its filing on SEDAR+ at www.sedarplus.ca.
contact method
Ken Deontemont | CEO, Medexus Pharmaceuticals
Phone: 905-676-0003 | Email: ken.dentremont@medexus.com
Marcel Conrad | Chief Financial Officer, Medexus Pharmaceuticals
Phone: 312-548-3139 | Email: marcel.konrad@medexus.com
Victoria Rutherford | Adelaide Capital
Phone: 480-625-5772 | Email: victoria@adcap.ca
forward-looking statements
Certain statements in this press release contain forward-looking information within the meaning of applicable securities laws, which are also referred to and/or referred to as “forward-looking information” or “forward-looking statements.” The words “anticipate,” “believe,” “expect,” “will,” “plan,” “potential” and similar words, phrases or expressions are generally intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. , phrase or expression. These statements are based on factors or assumptions used to draw conclusions or make projections or forecasts, including assumptions based on historical trends, current conditions and expected future developments. Because forward-looking statements relate to future events and conditions, by their nature they make assumptions and involve inherent risks and uncertainties. Medexus cautions that, although these assumptions are considered reasonable under the circumstances, these risks and uncertainties mean that actual results may differ from those contemplated by the forward-looking statements and may differ materially. Material risk factors include, but are not limited to, those set forth from time to time in Medexus’ filings with Canadian securities regulators, including Medexus’ most recent annual information form and management’s discussion and analysis. Accordingly, undue reliance should not be placed on these forward-looking statements, which are made only as of the date of this press release. Except as expressly required by law, Medexus assumes no obligation to update any forward-looking statements to reflect subsequent or other new information.
To view the source version of this release, please visit https://www.newsfilecorp.com/release/203575
[ad_2]
Source link